CPR Provides Fast, Affordable Repairs for Phones, Tablets, Laptops and Game Consoles

INDEPENDENCE, OH / ACCESSWIRE / April 30, 2019 / CPR Cell Phone Repair, the largest and fastest growing mobile repair franchise in North America, is expanding with a new location in Victoria, Texas. The network congratulates Michael and Becky Dietzel on the opening of their first location with the franchise, CPR Victoria.

To learn more about CPR Cell Phone Repair Victoria, please visit: https://www.cellphonerepair.com/victoria-tx/.

“We would like to welcome new store owners, Michael and Becky, to the network,” said Josh Sevick, CEO of CPR Cell Phone Repair. “With their experience and passion for the mobile repair industry, we know their team will succeed.”

CPR Victoria is conveniently located in the Town and Country Shopping Center near other thriving businesses. Michael and Becky’s team is ready to repair broken devices at budget-friendly prices. Customers can count on CPR Victoria to quickly repair their smartphones, tablets, laptops, game consoles, and more. As an added convenience, Michael and Becky’s team provides a limited lifetime warranty on every repair. Should the repaired device malfunction due to faulty replacement parts or a technician’s work, they will repair the device free of charge. Along with expert repairs and a limited lifetime warranty, the CPR Victoria team offers customers a free repair estimate before beginning any repair.

“We’ve lived here for ten years now, and we know the community has a need for professional and affordable device repairs,” said Michael and Becky. “We’re thrilled to provide the Victoria area with our services.”

With eight years of experience in the industry, Michael and Becky are experts when it comes to cell phone repairs. Michael graduated from Angelo State University and returned home to the Victoria area after graduating. When they’re not repairing devices and running their CPR store, Michael and Becky enjoy fishing and camping with their three sons. They’re currently remodeling their house, which takes up most of their free time. To learn more about the services Michael and Becky’s team offers, visit them at CPR Victoria.

CPR Cell Phone Repair Victoria is located at:

1305A East Airline Rd.

Victoria, TX 77901

Please contact the store at 361-746-1828 or via email: repairs@cpr-victoria.com

Please visit the website: https://www.cellphonerepair.com/victoria-tx/.

About CPR Cell Phone Repair:

Founded in Orlando, Fla. in 1996, CPR Cell Phone Repair is the fastest growing wireless technology franchise in North America and operates over 750 locations. As a pioneer and leader in the electronics repair industry, CPR offers same-day repair and refurbishing services for cell phones, laptops, gaming systems, digital music players, tablets, and other personal electronic devices. For four straight years, CPR was named in Entrepreneur Magazine’s Franchise 500 List. In 2019, CPR was ranked in the top 25 of the list and placed as the number one business for tech business franchises. For more information about CPR Cell Phone Repair and franchise opportunities, visit https://www.cellphonerepair.com/ or call 877-856-5101.

Contact:

Jeff Gasner
jeff@cellphonerepair.com
877-856-5101

SOURCE: CPR Cell Phone Repair

ReleaseID: 543489

Atlas Mara provides audited results for the year ended 31 December 2018

TORTOLA / ACCESSWIRE / April 30, 2019 / Atlas Mara Limited (“Atlas Mara” or the “Company” including its subsidiaries, the “Group”), the sub-Saharan African financial services group, releases its consolidated audited financial results for the year ended 31 December 2018. The results represent an extract from the audited summarised financial statements.

Principal financial highlights:

Reported net income of $39.7 million (2017: $45.4 million)
Underlying bank operating results include outperformance vs. 2017 in Nigeria and Zimbabwe, in-line performance in Botswana, Mozambique, and Rwanda, and underperformance in Tanzania and Zambia
In Nigeria, Union Bank of Nigeria (“UBN”) contributed associate income of an estimated $56.5 million for the period (2017: $38.4 million), which reflects the Company’s share of income on an equity accounted basis of $27.8 million (2017: $17.8 million), as well as the impact of the gain on acquisition of $28.7 million
EPS of 23 cents compared to 26 cents in 2017 pro forma for the 12 month impact of the 2017 equity issuance (2017 reported EPS: 42 cents)
Both the statement of financial position and profits of the Group were adversely impacted by the implementation of IFRS 9. This is consistent with the position reported by most banks across EMEA
Executed on Nigeria strategy by increasing stake in Union Bank of Nigeria (“UBN”) from approximately 44.5 percent in Q4 2017 to 49.0 percent in Q4 2018 and 49.7 percent as at 30 April 2019
The Group’s book value was adversely impacted by $59.1 million compared to 2017 and 1H 2018 due to the impact of the currency change in Zimbabwe
Post IFRS 9 impact, all operating banks maintained adequate capital adequacy ratios, reflecting stable balance sheets

Continued focus on deposit growth, loan book quality, and growth business lines:

Launched a deposit drive across Retail, Corporate and Institutional segments through innovative campaigns to lower cost of funds and generate sustainable funding for balance sheet growth
Reduction in non-performing loan (“NPL”) ratio to 11.1% at year-end (2017: 11.8%)
Digital channels volumes and revenues increasing month-on month across all channels, especially mobile banking (all countries), mobile push/pull (Zimbabwe) and POS (Mozambique and Zimbabwe)
Markets & Treasury pivoted to onshore, aligned to client demand, and continued expansion of product catalogue and client roster

Events Subsequent to Period End

The Group also announced today that it has entered into a binding term sheet with Equity Group Holdings Plc (“EGH”) for the exchange of certain banking assets of the Company in four countries for ordinary shares in EGH (the “Proposed Transaction”). The Proposed Transaction is subject to confirmatory due diligence, definitive transaction documentation, relevant regulatory approvals, and other conditions precedent customary for transactions of this nature. This transaction will result in the deconsolidation of the referenced entities effective 30 April 2019. Further information on the Proposed Transaction is included in the announcement issued by the Company today.
Following the announcement relating to the Proposed Transaction, the Company announces that John Staley has determined to step down as Chief Executive Officer effective 30 April 2019 to pursue other interests. The Board and the Company wish him well in his future endeavours. The Company’s executive leadership team will report directly to Executive Chairman Michael Wilkerson.

Additional Financial Highlights During the Period:

Credit impairments reduced to $0.2 million, driven by recoveries in Mozambique and Zambia and the overall improvement in credit quality compared to the IFRS 9 Day 1 position
2018 reported profit benefited from a gain of $28.7 million associated with the acquisition of additional shares in UBN, as a result of the fair value of the shares acquired exceeding the purchase consideration paid. It relates to both the additional shares allocated from the rights issue during January 2018 and the share purchase reported on 26 June 2018
Total revenue decreased by 11.2%, attributable to the decline in interest income on loans, as a result of contraction of the loan book, the impact of IFRS 9 on the accounting for interest in suspense, lower margins and tight market liquidity. Trading income declined due to lower trading volumes
Operating expenses increased by 7.6% driven by increases in the cost base of operating banks in most countries, most notably Zimbabwe which also saw a double-digit increase in inflation during 2018
The Group’s continued focus of managing down higher risk portfolios in certain countries where we had a cautious credit risk appetite has resulted in a further improved NPL ratio, but combined with the impact of IFRS 9 the total loan book contracted by 13.2%
Asset recoveries totalled $6.0 million for the year reflecting continued focus to deliver shareholder value through managing the asset portfolio

Financial highlights from the UBN results included:

Profit after tax increased by 39% to 18 billion Nigerian Naira ($59 million)
Returns on average tangible equity at the bank increased from 5.9% to 11.3%
NPL ratio declined from 20.8% to 8.1% resulting from loan book clean-up, improved collections and collateral management, and adoption of IFRS 9
Total expenses increased by 12%, largely due to higher AMCON/Nigerian Deposit Insurance Corporation (NDIC) premium, increased depreciation and maintenance expenses, staff costs and business promotion expenses
Loans and advances reduced by 8% mainly as a result of write-off of some fully provisioned non-performing loans
Deposits increased by 7%, reflecting the success of the bank’s mobilization efforts
BVPS declined to ₦7.75, a decline of 36.1% from 2017, which resulted primarily from loan book clean-up including IFRS 9 adoption

Key operational highlights during the period:

Continued focus on strengthening the existing retail and corporate business platform across all countries of operation. In 2018 we increased focus on operational and IT improvements, and talent acquisition in the banks
Launched a deposit drive across Retail, Corporate and Institutional segments through innovative campaigns across the franchise to lower cost of funds and generate sustainable funding
Launched improved corporate transaction platforms and improved mobile banking applications for USSD, Android and iOS in Mozambique, Rwanda, Tanzania and Zambia. The POS offering was enhanced in Zimbabwe to include mobile money while MPOS was introduced for the SME clients
Digital channels volumes and revenues, though on a small scale relative to total revenues, have been increasing month-on-month across all channels, especially mobile banking (all countries), mobile push/pull (Zimbabwe) and POS (Mozambique and Zimbabwe)
Strong performance in the Markets & Treasury Business in Zambia, Rwanda and Tanzania. In Mozambique we led the first ever secondary market transaction on fixed income trading and executed the issuance of BancABC Mozambique corporate paper

Botswana:

Completed an IPO for 20.5% of the shares in issue, raising $28.1 million for ABCH Holdings, a portion of which has been reinvested in the ongoing efforts to develop and enhance the Group’s IT infrastructure and banking platforms
Raised $15 million from the market to refinance Tier 2 Capital
Renegotiated a three-year retail savings and loans scheme with two of the largest employee unions with a combined membership of 80,000 members
Officially launched a prepaid Pula card to public service employees. If we achieve our goal of 200,000 cards issued in the next 24 months our Botswana franchise will become the largest card issuer in the market
Partnered with one of the biggest telecom companies for the issuance of the telco’s mobile wallet prepaid card

Launched an online cash management solution with an automatic banking machine at client premise for Corporate and SME customers
Initiated a micro-credit pilot with 19,000 mobile wallet subscribers of one of the biggest telecoms companies in Mozambique with a planned market-wide launch in 2019
Launched a new Corporate and Retail online transactional platform with enhanced functionality and client experience

Rwanda:

Continue to grow our presence in the Corporate Banking space. During 2018 we:

Participated in a $50 million syndicated loan for a large MNO as lead arranger and extended financing ($11 million) for infrastructure expansion and modernization

Participated in the funding of a Corporate client contracted to construct a new Airport

Launched a new pre-export value chain financing in the country’s coffee sector

Obtained VISA license and commenced integration process

Launched a virtual card in partnership with the leading Mobile Network Operator in the market and Mastercard. This is the first of its kind in the Tanzanian market. The virtual card will allow MNO mobile wallet holders to make payments on any local or international website

Zambia:

Launched an improved mobile banking application and a mobile wallet for both savings and micro-credit with multi-lingual functionality to support the Bank’s financial inclusion drive
Strong performance in Corporate Banking with new advances to our Corporate clients rising 150% compared to 2017
Commenced rollout of 90 new ATMs with upgraded functionality. The ATMs are bringing new features like card-less transactions and cash deposit facilities
Successfully completed the rebranding of the merged bank and was awarded second place for brand equity conducted by IPSOS, a global market research and a consulting firm

Zimbabwe:

Executed on our liability-led strategy which resulted in Current and Savings accounts contribution to total liabilities improving to 57% from 50% in 2017
Introduced new Agribusiness unit to take advantage of potential growth in the Agricultural sector, expected to become a major contributor to the country’s GDP. New products specifically suited to small scale farming customers have been developed with a significance increase in funding to our agri-finance clients
Raised large funding facility as the second tranche of the Public sector road infrastructure programme
Renewed significant stock financing facility with one of the biggest players in the agricultural sector
Utilized partnership with one of the strongest insurance players in the market to serve the Retail& SME segments better through the issuance of zero-deposit mortgage advance and performance bonds and bid bonds
Partnered with World Remit, a global leader in international transfers to mobile money accounts, to enable the bank to participate in diaspora remittances processing

Investor Conference Call

Atlas Mara will be holding a conference call for investors at 10am EST / 3pm BST today. There will be a presentation available in the Investor Relations section of the Company’s website, http://atlasmara.com. The Company will not be disclosing any new material information.

United States: +1 631 913 1422

United Kingdom: +44 3333000804

Contact Details:

Investors

Media

Teneo, +44 (20) 7260 2700

Anthony Silverman

About Atlas Mara

Atlas Mara Limited (LON: ATMA) is a financial services institution founded by Bob Diamond and listed on the London Stock Exchange. With a presence in seven sub-Saharan countries, Atlas Mara aims to be a positive disruptive force in the markets in which we operate by leveraging technology to provide innovative and differentiated product offerings, deliver excellent customer service and accelerate financial inclusion. For more information, visit www.atlasmara.com.

Click on, or paste the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/5232X_1-2019-4-30.pdf

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Atlas Mara

ReleaseID: 543487

Strategic partnership delivers end-to-end onboarding solution for corporate and investment banks

NEW YORK, NY / ACCESSWIRE / April 30, 2019 / Arachnys, the leader in Customer Risk Intelligence solutions for Know Your Customer (KYC), Anti Money Laundering (AML) and Enterprise Due Diligence (EDD), have entered into a technology partnership with Pegasystems Inc. (PEGA), the software company empowering digital transformation at the world’s leading enterprises. By unifying Pega KYC and Pega CLM with Arachnys’ Customer Risk Intelligence platform, financial institutions can further improve risk mitigation and efficiency in their overall onboarding and KYC processes.

This partnership will enable customers of Pega and Arachnys to consume Arachnys content within Pega CLM and Pega KYC solutions. Clients can further streamline their due diligence processes and ensure all relevant data is in one place with a single view of the new customer, driving further digitization and efficiency.

”Today’s financial institutions strive to further simplify the complexity of client onboarding while meeting complex regulatory requirements and mitigating risk,” said Reetu Khosla, industry market leader, CLM & KYC banking technology, Pegasystems. ”By partnering with Arachnys, we are enabling banks to further digitize client onboarding through smart data management – our clients can drive efficiency through the automation of due diligence data within the client onboarding and KYC lifecycle.”

”We are thrilled to partner with Pegasystems and offer the market a seamless solution that accelerates the ability to validate and enhance customer, and UBO data, for rapid onboarding and revenue acquisition,” said Ed Sander, President of Arachnys. ”Increasingly, financial institutions are adopting cloud platforms that leverage advanced technologies, such as our joint offering with Pegasystems, to support business growth, while addressing evolving compliance needs.”

Named the industry category leader in CLM and KYC applications year over year, most recently by leading independent industry risk technology analyst firm Chartis, Pega CLM and Pega KYC provide large complex financial institutions with pre-defined industry best practices, including over 30,000 KYC rules for multi-jurisdiction and multi-product onboarding. Pega is the only vendor that provides a cross line-of-business solution – including corporate, institutional, wealth, and retail – and globally scalable CLM and KYC applications with inherent digital process automation, rules, process, case management, AI, and robotics. These industry-leading applications can be deployed in as little as three months to drive real outcomes from front to back office.

About Arachnys:

Arachnys is a leader in cloud solutions for assessing financial crime customer risk, ensuring compliance for new regulatory CDD, KYC and EDD requirements and accelerating topline revenue. Financial institutions around the world rely on Arachnys’ financial crime risk assessment platform, machine learning algorithms and data harnessing technology to standardize and improve efficiency of compliance processes, reduce onboarding costs and improve the customer experience. Three of the world’s top 10 financial institutions and four of the world’s top 10 accountancy companies utilize Arachnys solutions for their financial crime risk assessment needs. Celent, a leading financial services research and advisory firm, recently recognized Arachnys for its innovative Robotic Process Automation solution for KYC/EDD.

Arachnys is the registered trademark of Arachnys Information Services, headquartered in London with offices in New York. The Arachnys logos and product brands are trademarks/service marks of Arachnys. For more information please visit www.arachnys.com.

Media Contact

Lynne Morrice
lynne.morrice@arachnys.com
+44 (0) 7973 143330

SOURCE: Arachnys

ReleaseID: 543394

JUPITER, FL / ACCESSWIRE / April 30, 2019 / Dyadic International, Inc. (”Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, is pleased to announce it has entered into a worldwide sub-licensing agreement with Australian based drug development and contract manufacturing organization, Luina Bio Pty Ltd (”Luina Bio”), for the development and commercialization of certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals using Dyadic’s proprietary C1 gene expression platform.

Dyadic’s Chief Executive Officer, Mark Emalfarb, said ”We are very excited to announce this sub-licensing agreement with Luina Bio. Luina Bio has over 20 years of GMP contract manufacturing and drug development experience in human and animal health products, including recombinant proteins and vaccines.” Matthew Jones, Dyadic’s Chief Commercial Officer added that, ”we believe that our proprietary C1 gene expression platform coupled with Luina Bio’s animal health drug development expertise will bring us another step closer to achieving our mission to help speed the development and lower the cost of biologic drugs for human and animal health.”

Luina Bio’s Executive Chairman, Chris Burrell, said ”We are thrilled to be working with Dyadic to develop and commercialize a number of targeted products for use in the prevention and treatment of various ailments for companion animals.” Mr. Burrell further commented, ”Continued population growth, urbanization and rising per capita income is seeing the rate of pet ownership globally continue to rise year on year. As pet ownership rates continue to rise so too will the standard of living for pets. In turn, animal health medicines and vaccines will be required in greater volumes. Our goal is to utilize Dyadic’s C1 proprietary gene expression platform to not only speed up the development of new animal health medicines and vaccines but to lower the cost for such products making them more accessible to more people and their pets.”

Under the worldwide sub-licensing agreement, Dyadic will receive 20% equity in a new joint venture company, Novovet Pty Ltd, and a percentage of royalties on net sales and non-sales revenue which incorporates Dyadic’s proprietary C1 gene expression platform.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic’s website at http://www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

About Luina Bio

Luina Bio is a Brisbane, Australia based drug development and contract manufacturing organization (CMO) serving the pharmaceutical, biotechnology and veterinary industries. Drawing on more than 20 years of contract manufacturing experience, Luina Bio has the scientific expertise, training and experience to ensure a successful outcome to any project. Utilizing its TGA/APVMA licensed facilities operating to international cGMP standards, Luina Bio provides a comprehensive suite of manufacturing services for both biological and small molecule drugs. Luina Bio has extensive experience in manufacturing recombinant proteins, live therapeutics, whole cell vaccines, viral vaccines, purified plant extracts and pro-biotics for pre-clinical, phase 1 to 3 human clinical trials and commercial products for veterinary industry for clients both within Australia and internationally in the United States, Europe and Asia.

In 2017 Luina Bio was the winner of the Queensland Government Export Awards for the Health and Biotechnology Industry and in 2018 was a winner in the Westpac Banking Top 200 Businesses of Tomorrow.

Learn more about Luina Bio https://luinabio.com.au/

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as ”anticipate,” ”believe,” ”could,” ”estimate,” ”expect,” ”goal,” ”intend,” ”look forward to,” ”may,” ”plan,” ”potential,” ” predict,” ”project,” ”should,” ”will,” ”would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic’s and third parties research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on key customers and collaborators; (8) the pharmaceutical and biotech industry, governmental regulatory and other agencies’ willingness to adopt, utilize and approve the use of the C1 gene expression platform; and (9) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption ”Risk Factors” in our December 31, 2018 Annual Report filed with the SEC on the Form 10-K on March 27, 2018. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.

Contact:

Dyadic International, Inc.
Ping W. Rawson
Chief Accounting Officer
Phone: (561) 743-8333
Email: prawson@dyadic.com

Luina Bio Pty Ltd
Chris Burrell
Executive Chairman
Phone: +61 (0)47 832 153
Email: mailto:chris.burrell@luinabio.com.au

SOURCE: Dyadic International, Inc.

ReleaseID: 543398

JACKSONVILLE, FL / ACCESSWIRE / April 30, 2019 / Duos Technologies Group, Inc. (“Duos” or the “Company”) (OTCQB: DUOT), a provider of intelligent security analytical technology solutions, is scheduled to participate at the following financial conferences during the month of May 2019:

Event: The ThinkEquity Conference
Date: May 2, 2019
Presentation: Thursday, May 2 at 1:30 p.m. Eastern time
Location: The Mandarin Oriental Hotel in New York, NY
Executive: CFO Adrian Goldfarb

Event: Rocky Mountain Microcap Conference IV
Date: May 7, 2019
Presentation: Tuesday, May 7 at 3:30 p.m. Eastern time
Location: Coors Field in Denver, CO
Executive: CFO Adrian Goldfarb

Event: 20th Annual B. Riley FBR Investor Conference
Dates: May 22-23, 2019
Presentation: Wednesday, May 22 at 11:30 a.m. Eastern time
Location: The Beverly Hilton Hotel in Beverly Hills, CA
Executive: CFO Adrian Goldfarb

For additional information or to schedule a one-on-one meeting with Duos management, please contact Duos’ IR team at (949) 574-3860 or DUOT@liolios.com.

About Duos Technologies Group, Inc.

Duos Technologies Group, Inc. (OTCQB: DUOT), based in Jacksonville, Florida, through its wholly owned subsidiary, Duos Technologies, Inc., provides advanced intelligent security and analytical technology solutions with a strong portfolio of intellectual property. The Company’s core competencies include intelligent technologies that combine machine learning, artificial intelligence and advanced video analytics that are delivered through its proprietary integrated enterprise command and control centraco® platform. The Company provides its broad range of technology solutions with an emphasis on mission critical security, inspection and operations within the rail transportation, retail, petrochemical, government, and banking sectors. Duos Technologies also offers professional and consulting services for large data centers. For more information, visit www.duostech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes”, “expects”, “may”, “will”, “should”, “anticipates”, “plans”, or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, which could cause Duos Technologies Group, Inc.’s actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to, those described in Item 1A in Duos’ Annual Report on Form 10-K, which is expressly incorporated herein by reference, and other factors as may periodically be described in Duos’ filings with the SEC.

Contacts: Duos Technologies

Corporate

Tracie Hutchins
Duos Technologies Group, Inc.
(904) 652-1601
tlh@duostech.com

Investor Relations

Matt Glover or Tom Colton
Liolios
(949) 574-3860
DUOT@liolios.com

SOURCE: Duos Technologies Group, Inc.

ReleaseID: 543415